Embolic risk in atrial fibrillation that arises from hyperthyroidism: Review of the medical literature

Texas Heart Institute Journal

Volumn 38, Issue 3, 2011, Pages 225-228

  Traube, Elie ^a   Coplan, Neil L ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Anticoagulants administration Dosage; Atrial fibrillation drug therapy; Clinical trials as topic; Embolism prevention Control; Evidencebased medicine; Heart diseases physiopathology; Hyperthyroidism complications epidemiology; Randomized controlled trials as topic; Risk factors; Thromboembolism prevention Control; Thyrotoxicosis complications

Indexed keywords

LIOTHYRONINE;

ANTICOAGULATION; ARTERY EMBOLISM; BLOOD CLOTTING; CARDIOVERSION; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ARRHYTHMIA; HORMONE ACTION; HUMAN; HYPERTHYROIDISM; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; THYROTOXICOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; HUMANS; HYPERTHYROIDISM; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; THYROTOXICOSIS;

EID: 79960006709     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):546S-92S.
2. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Ryden LE, Cannom DS, Crijns HJ, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) [published erratum appears in J Am Coll Cardiol 2007;50(6):562]. J Am Coll Cardiol 2006;48 (4):854-906.
3. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977;7 (6):481-93.
4. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26(1):189-218.
5. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988;19(1):15-8.
6. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965;31:888-98.
7. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WC, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2008;168(20):2219-24.
8. Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008;5(3):170-6.
9. Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev 2004;12(6):299-305.
10. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or f lutter: a population-based study [published erratum appears in Arch Intern Med 2005;165(3): 307]. Arch Intern Med 2004;164(15):1675-8.
11. Haynes JH 3rd, Kageler WV. Thyrocardiotoxic embolic syndrome. South Med J 1989;82(10):1292-3.
12. Siegel D. Thyrotoxicosis, atrial fibrillation, and a cerebral vascular accident in a young woman. Am J Emerg Med 2001;19 (7):605-6.
13. Staffurth JS, Gibberd MC, Fui SN. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977;2(6088): 688-90.
14. Yuen RW, Gutteridge DH, Thompson PL, Robinson JS. Embolism in thyrotoxic atrial fibrillation. Med J Aust 1979;1(13): 630-1.
15. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141(9):1191-2.
16. Hurley DM, Hunter AN, Hewett MJ, Stockigt JR. Atrial fibrillation and arterial embolism in hyperthyroidism. Aust N Z J Med 1981;11(4):391-3.
17. Cacciatori V, Bellavere F, Pezzarossa A, Dellera A, Gemma ML, Thomaseth K, et al. Power spectral analysis of heart rate in hyperthyroidism. J Clin Endocrinol Metab 1996;81(8): 2828-35.
18. Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res 2009;2(1):4.
19. Nadkarni PJ, Sharma M, Zinsmeister B, Wartofsky L, Burman KD. Thyrotoxicosis-induced ventricular arrhythmias. Thyroid 2008;18(10):1111-4.
20. Resnick LM, Laragh JH. Plasma renin activity in syndromes of thyroid hormone excess and deficiency. Life Sci 1982;30(7-8):585-6.
21. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993;87(5):1435-41.
22. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996;6(5):505-12.
23. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344(7):501-9.
24. Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009;35(3):288-94.
25. Erem C, Ersoz HO, Karti SS, Ukinc K, Hacihasanoglu A, Deger O, Telatar M. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002;25(4): 345-50.
26. Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 2010;41(5):961-6.
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classif ication schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
28. Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989;117(4):976-7.